Kirin vs Chugai Pharmaceutical Co.: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Kirin Holdings Co. Ltd. (2503.JP)

Q3 20266 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

September 20266 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

Latest6 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

Chugai Pharmaceutical Co., Ltd. (4519.JP)

Q3 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

August 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

Latest24 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.